Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Cabozantinib Active in Carcinoid Tumors and Pancreatic NETs

February 8th 2018

Jennifer A. Chan, MD, discusses the significance of the phase II results of cabozantinib in patients with carcinoid tumors and pancreatic NETs.

Dr. Bekaii-Saab Discusses the ReDOS Study in Metastatic CRC

February 6th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the phase II regorafenib (Stivarga) dose optimization study (ReDOS) in metastatic colorectal cancer.

Kulke Sheds Light on Emerging Agents for Neuroendocrine Tumors

February 6th 2018

Matthew Kulke, MD, discusses the evolving treatment paradigm for patients with neuroendocrine tumors.

Dr. Pishvaian on Molecular Alteration in Pancreatic Cancer

February 6th 2018

Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown University Lombardi Comprehensive Cancer Center, discusses the background of a study investigating molecular alterations for patients with pancreatic cancer.

Dr. Abou-Alfa on Sequencing Agents in the Treatment of Patients With HCC

February 3rd 2018

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses how the potential approval of cabozantinib (Cabometyx) in hepatocellular carcinoma (HCC) could affect the treatment landscape in liver cancer.

Dr. Singh Discusses the Future of Immunotherapy in GIST

February 1st 2018

Arun S. Singh, MD, associate professor, UCLA David Geffen School of Medicine, discusses the future of immunotherapy in gastrointestinal stromal tumors (GIST).

Dr. Jarnagin on Surgical Protocols for CRC That Have Spread Beyond the Liver

February 1st 2018

William R. Jarnagin, MD, FACS, chief, Hepatopancreatobiliary Service, Benno C. Schmidt Chair, Surgical Oncology, Memorial Sloan Kettering Cancer Center, discusses the surgical barriers in treating patients with colorectal cancer that has metastasized outside of the liver.

Expert Shares Insight on Napabucasin Plus Pembrolizumab in mCRC

February 1st 2018

Akihito Kawazoe, MD, discusses the study of napabucasin plus pembrolizumab in mCRC.

Dr. Ramirez Discusses Treating Patients With NETs of the Lung

January 31st 2018

Robert Ramirez, DO, FACP, Ochsner Medical Center, discusses treating patients with neuroendocrine tumors (NETs) of the lung.

Immunotherapy Active in Advanced GISTs

January 31st 2018

Arun S. Singh, MD, discusses the developing role of immunotherapy in patients with GISTs, particularly the randomized phase II trial investigating nivolumab as a single agent and in combination with ipilimumab.

Dr. Kardosh Discusses Epacadostat in Gastric/GEJ Adenocarcinoma

January 30th 2018

Adel Kardosh, MD, postdoctoral medical fellow, oncology, Stanford Medicine, discusses epacadostat in gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Dr. Zhu Discusses Findings of the KEYNOTE-224 in HCC

January 30th 2018

Andrew Zhu, MD, PhD, director, Liver Cancer Research, Medicine, Massachusetts General Hospital, discusses the findings of KEYNOTE-224 in hepatocellular carcinoma (HCC).

Dr. Karasic on Palbociclib in Esophageal and Gastric Cancer

January 30th 2018

Thomas Karasic, MD, investigator at Penn Medicine, discusses the rationale behind the phase II trial (NCT01037790) of palbociclib (Ibrance) in patients with advanced esophageal or gastric cancer.

Entrectinib Effective in Pancreatic Cancer Subgroup

January 29th 2018

Michael J. Pishvaian, MD, PhD, discusses the findings with entrectinib in this population, as well as the potential implications of widespread molecular testing in pancreatic cancer.

Dr. Janjigian on Immunotherapy in Esophageal and Gastric Cancer

January 26th 2018

Yelena Y. Janjigian, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of immunotherapy for patients with gastric and esophageal cancer.

FDA Approves Lutathera for GEP-NETs

January 26th 2018

The FDA has approved Lutathera for the treatment of patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

Dr. Singh Discusses Immunotherapy Study in GIST

January 26th 2018

Arun S. Singh, MD, Ronald Reagan UCLA Medical Center, discusses the rationale behind a randomized phase II study (NCT02880020) of nivolumab (Opdivo) monotherapy versus nivolumab with ipilimumab (Yervoy) in patients with metastatic or unresectable gastrointestinal stromal tumors (GIST).

Dr. Andre on Nivolumab Plus Ipilimumab in dMMR/MSI-H mCRC

January 25th 2018

Thierry Andre, MD, professor of medical oncology, University Pierre et Marie Curie (UMPC), and Head of the Medical Oncology Department in St. Antoine Hospital, Assistance Publique Hôpitaux de Paris, discusses the results of the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) in patients with DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer.

Radiofrequency Ablation Improves Survival Over SBRT in Localized HCC

January 24th 2018

Radiofrequency ablation was associated with superior 5-year overall survival compared with stereotactic body radiotherapy for patients with localized hepatocellular carcinoma.

Nivolumab Alone or With Ipilimumab Provides Durable Benefit in MSI-H/dMMR mCRC

January 24th 2018

Data from the CheckMate-142 study support the use of nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy) for the treatment of patients with previously treated DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer.